(Q64112087)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

meta-analysis

0 references

title

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

main subject

phase II clinical trial

1 reference

M Van Glabbeke

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

J Verweij

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

I Judson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

O S Nielsen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

EORTC Soft Tissue and Bone Sarcoma Group

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

language of work or name

English

0 references

publication date

1 March 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

7 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

volume

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

page(s)

543-549

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Clinical trial designs for cytostatic agents: are new approaches needed?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Phase II study of raltitrexed (‘Tomudex’) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Asymptotically Efficient Rank Invariant Test Procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Planned versus attained design in phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Incorporating toxicity considerations into the design of two-stage phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

An optimal three-stage design for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900398-7

7 January 2021

10.1016/S0959-8049(01)00398-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11872347%20AND%20SRC:MED&resulttype=core&format=json

7 December 2019

1 reference